In the first two months of 2025, 4,4 million packages of antacid drugs worth 2 billion rubles (retail prices, including VAT) were sold in Russia, according to data from RNC Pharma. This represents a 9,9% increase in sales volume compared to the same period in 2024, with a ruble increase of 18,8%. Domestic manufacturers accounted for the majority of this growth, with sales of their products rising 78% in physical terms and 2,3 times in rubles.
Despite this progress, the total market share of Russian brands remains small, at 13,6% in packages and 9% in rubles, analysts say. However, this marks a steady increase over the past three years; in 2022, domestic manufacturers held only 3,2% of the market in packages and 2,2% in rubles. Among the top performers boosting y-o-y growth in January-February 2025 were Renewal’s Gasit (increasing 4,6 times in rubles), ABBA’s Malvacid (2,5 times), and Valenta’s Antareit (2,4 times).
The leading product in retail sales during this period was Sanofi’s Phosphalugel, with a 28,5% market share and a sales growth rate of 21% in Russian currency. It was followed closely by Teva’ss Almagel, which accounted for 28,2% of the market, and Bayer Healthcare’s Rennie, with a 16% share.
In of 2024, 24 million packages of antacids were sold in Russia, reflecting a 5,4% increase from 2023. Total sales reached 10.6 billion rubles, a 19,1% rise compared to the previous year. In-kind sales increased by 5,4%, while ruble sales surged by 19,1%. The increase was also almost entirely provided by domestic companies, with foreign products losing 1% in packages. However, foreign products still saw a 15% increase in ruble sales against a backdrop of rising prices.
Earlier, RNC Pharma reported that the retail market for hepatoprotectors and lipotropics demonstrated the highest sales growth in Russia since the beginning of 2025, with 4,1 million packages sold at retail for 5,1 billion rubles.
